Life Extension Update
Coenzyme Q10 supplementation lowers interleukin-6 and provides antioxidant benefits in coronary artery disease patients
Friday, March 16, 2012. Inflammation plays a role in the development of heart disease, the leading cause of death in the Western world. While coenzyme Q10 (CoQ10) supplementation can benefit the heart, few studies have investigated its role in protecting against inflammation in heart disease patients.
In a trial described in an article published on February 16, 2012 in the journal Nutrition, researchers at Chung Shan Medical University in Taiwan compared the effects of twelve weeks of supplementation with 60 or 150 milligrams per day of CoQ10, or a placebo in 40 men and women with coronary artery disease. Plasma CoQ10 levels, markers of inflammation including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 and homocysteine; malondialdehyde (a marker of lipid peroxidation) and levels of the antioxidant enzyme superoxide dismutase (SOD) were measured before and after the treatment period.
At the beginning of the study, having a higher CoQ10 level was associated with a lower level of interleukin-6 and C-reactive protein. By the end of the treatment period, plasma coenzyme Q10 levels increased in both groups that received the supplement. Among those who received the higher dose, interleukin-6 levels decreased by 14 percent and malondialdehyde levels were significantly lower by the end of the trial compared to baseline levels. Both groups that received CoQ10 experienced greater SOD activity. A non-significant reduction in hs-CRP values was observed in association with CoQ10 supplementation.
"Cell culture experiments have demonstrated that coenzyme Q10 can moderate the anti-inflammatory effects of antioxidant activities and by nuclear factor-kappa beta1–dependent gene expression," they write. "In the present study, coenzyme Q10 supplements at a dose of 150 milligrams showed a significant antioxidization effect in decreasing the malondialdehyde level and slightly increasing SOD activities after 12 weeks of intervention."
"Coenzyme Q10 supplementation at a dosage of 150 milligrams appears to decrease the inflammatory marker interleukin-6 in patients with coronary artery disease," the authors conclude. "Long-term studies are needed to establish the beneficial effects of higher-dosage coenzyme Q10 supplementation on inflammation in patients with coronary artery disease."
FernBlock® is a registered trademark of Industrial Farmaceutica Cantabria, S.A. Patent pending SendaraTM is a trademark of Nutragenesis, LLC.
This supplement should be taken in conjunction with a healthy diet and regular exercise program. Individual results are not guaranteed and results may vary.
The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.
If you are not 100% satisfied with any purchase made directly from Life Extension®, just return your purchase within 12 months of original purchase date and we will either replace the product for you, credit your original payment method or credit your Life Extension account for the full amount of the original purchase price (less shipping and handling).
These statements have not been evaluated by the Food and Drug Administration.
These products are not intended to diagnose, treat, cure, or prevent any disease.